Evidence map›Paper›PMID 32983617›Full record

ArticleNeurology. Clinical practice2020

Practice Current: How do you manage mild cognitive impairment?

Aravind Ganesh, Padmaja Genesh, Malik M Adil, Malavika Varma, Eric E Smith

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Neurology. Clinical practice, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.5field-weighted citation impact, top 37% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 3 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 2 countries.

Aravind GaneshDepartment of Clinical Neurosciences (AG), University of Calgary; Learning and Support Services (PG), Alzheimer Society of Calgary, Canada; Johns Hopkins University School of Medicine (MMA), Bethesda, MD; Advanced Health Analytics (AHA Health Ltd) (MV), Calgary, and Katthy Taylor Chair in Vascular Dementia (EES), Department of Clinical Neurosciences, University of Calgary, Canada.ORCID 0000-0001-5520-2070
Padmaja GeneshDepartment of Clinical Neurosciences (AG), University of Calgary; Learning and Support Services (PG), Alzheimer Society of Calgary, Canada; Johns Hopkins University School of Medicine (MMA), Bethesda, MD; Advanced Health Analytics (AHA Health Ltd) (MV), Calgary, and Katthy Taylor Chair in Vascular Dementia (EES), Department of Clinical Neurosciences, University of Calgary, Canada.
Malik M AdilDepartment of Clinical Neurosciences (AG), University of Calgary; Learning and Support Services (PG), Alzheimer Society of Calgary, Canada; Johns Hopkins University School of Medicine (MMA), Bethesda, MD; Advanced Health Analytics (AHA Health Ltd) (MV), Calgary, and Katthy Taylor Chair in Vascular Dementia (EES), Department of Clinical Neurosciences, University of Calgary, Canada.ORCID 0000-0002-4635-6462
Malavika VarmaDepartment of Clinical Neurosciences (AG), University of Calgary; Learning and Support Services (PG), Alzheimer Society of Calgary, Canada; Johns Hopkins University School of Medicine (MMA), Bethesda, MD; Advanced Health Analytics (AHA Health Ltd) (MV), Calgary, and Katthy Taylor Chair in Vascular Dementia (EES), Department of Clinical Neurosciences, University of Calgary, Canada.
Eric E SmithDepartment of Clinical Neurosciences (AG), University of Calgary; Learning and Support Services (PG), Alzheimer Society of Calgary, Canada; Johns Hopkins University School of Medicine (MMA), Bethesda, MD; Advanced Health Analytics (AHA Health Ltd) (MV), Calgary, and Katthy Taylor Chair in Vascular Dementia (EES), Department of Clinical Neurosciences, University of Calgary, Canada.
Johns Hopkins University · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Mild cognitive impairment (MCI) is characterized by evidence of cognitive impairment with minimal disruption of instrumental activities of daily living and carries a substantial risk of progression of dementia. Whereas current guidelines support a relatively minimalistic workup to identify reversible or structural causes, the field has witnessed the rapid development of various sophisticated imaging, biomarker, and genetic investigations in the past few years. The role of these investigations in routine practice is uncertain. Similarly, although there are no approved treatments for MCI, neurologists may experience uncertainty about using cholinesterase inhibitors or other medications or supplements that have been studied in MCI with limited success, particularly when patients or families are keen to try pharmacologic options. Given these uncertainties, and the paucity of high-quality data in the literature, we sought expert opinion from around the globe on how to investigate and treat patients with MCI. Similar questions were posed to the rest of our readership in an online survey, the preliminary results of which are also presented.

Identifiers

PMID32983617
PMCPMC7508330
OpenAlexW3042102383

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.